Scarica l'app Stockscreener
7.58
2.02%
0.15
Dopo l'orario di chiusura:
7.72
0.14
+1.85%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Precedente Chiudi:
$7.43
Aprire:
$7.54
Volume 24 ore:
9.05M
Relative Volume:
0.36
Capitalizzazione di mercato:
$7.94B
Reddito:
$113.29M
Utile/perdita netta:
$-351.47M
Rapporto P/E:
-19.45
EPS:
-0.3898
Flusso di cassa netto:
$-309.19M
1 W Prestazione:
+8.91%
1M Prestazione:
+3.84%
6M Prestazione:
+252.56%
1 anno Prestazione:
+260.95%
Intervallo 1D:
$7.43
$7.77
Intervallo di 1 settimana:
$6.73
$7.77
Portata 52W:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Nome
Immunitybio Inc
Settore
Industria
Telefono
(844) 696-5235
Indirizzo
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.58 | 7.78B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-12 | Ripresa | BTIG Research | Buy |
| 2025-05-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | BTIG Research | Buy |
| 2023-05-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Iniziato | Jefferies | Buy |
Mostra tutto
Immunitybio Inc Borsa (IBRX) Ultime notizie
ImmunityBio, Inc. Securities Fraud Class Action Result of - GlobeNewswire
IBRX Lead Plaintiff Deadline is May 26, 2026Injured Stockholde - The National Law Review
IBRX Stock Jumps After-Hours: Bulls Cheer ‘Unstoppable’ Global Expansion Amid US Regulatory Heat For Anktiva - Stocktwits
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Morningstar
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - PR Newswire
INVESTOR DEADLINE ALERT: ImmunityBio, Inc. (IBRX) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Globe and Mail
ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting - BioSpace
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
IBRX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week - Stocktwits
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
IBRX Deadline Alert: The Gross Law Firm Reminds ImmunityBio, Inc. (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - GlobeNewswire
IBRX Stock Lights Up: Retail Cheers Calls For Trump To ‘Pull The Plug’ On FDA Chief Marty Makary Amid Anktiva Row - Stocktwits
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm - Morningstar
ImmunityBio to Report Q1 Earnings: What's in the Cards? - Yahoo Finance
IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - GlobeNewswire Inc.
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026 Filing Deadline in Securities Class ActionContact Lieff Cabraser - marketscreener.com
IBRX stock climbs overnight: ImmunityBio declares 'all systems go' for Dunkirk Anktiva manufacturing push - MSN
IBRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Is ImmunityBio, Inc. (IBRX) A Good Stock To Buy Now? - Insider Monkey
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - mydailyrecord.com
IBRX Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages IBRX Investors with Losses to Contact the Firm - PR Newswire
D. Boral Capital Maintains ImmunityBio (IBRX) Buy Recommendation - MSN
symbol__ Stock Quote Price and Forecast - CNN
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
ANKTIVA Strong Demand Propels ImmunityBio, Inc. (IBRX) to Robust Revenue Growth - Insider Monkey
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc.IBRX - Morningstar
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmIBRX - TMX Newsfile
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. - GlobeNewswire
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA - GlobeNewswire
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - GlobeNewswire Inc.
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
IBRX Forecast, Price Target & Analyst Ratings | IMMUNITYBIO INC (NASDAQ:IBRX) - ChartMill
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming DeadlinesIBRX - PR Newswire
ImmunityBio Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
IMMUNITYBIO, INC. (IBRX) SHAREHOLDER ALERT Bernstein - GlobeNewswire
IBRX Lawsuit Alleges Chairman Allegedly Overstated Drug CapabilitiesImmunityBio Investors Face Losses Following Chairman Allegedly Overstated Drug Capabilities: SueWallSt - PR Newswire
Bladder Cancer Vaccines Market to Reach USD 1,365.83 Million - openPR.com
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
IBRX Lawsuit Alleges Chairman Allegedly Overstated Drug Capabili - GuruFocus
IBRX DEADLINE NOTICE: ImmunityBio, Inc. Investors Encouraged to Contact Kirby McInerney LLP By May 26, 2026 - ACCESS Newswire
ImmunityBio (NASDAQ: IBRX) pairs ANKTIVA surge with 2026 director, auditor votes - Stock Titan
[ARS] ImmunityBio, Inc. SEC Filing - Stock Titan
Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc. - The Joplin Globe
NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc. - The Globe and Mail
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who - GlobeNewswire
Immunitybio Inc Azioni (IBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):